Related references
Note: Only part of the references are listed.Immunomodulatory drugs act as inhibitors of DNA methyltransferases and induce PU.1 up-regulation in myeloma cells
Shinya Endo et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2016)
The KDM3A-KLF2-IRF4 axis maintains myeloma cell survival
Hiroto Ohguchi et al.
NATURE COMMUNICATIONS (2016)
Identification of cereblon-binding proteins and relationship with response and survival after IMiDs in multiple myeloma
Yuan Xiao Zhu et al.
BLOOD (2014)
International Myeloma Working Group Consensus Statement for the Management, Treatment, and Supportive Care of Patients With Myeloma Not Eligible for Standard Autologous Stem-Cell Transplantation
Antonio Palumbo et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells
Jan Kroenke et al.
SCIENCE (2014)
The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins
Gang Lu et al.
SCIENCE (2014)
PU.1 is a potent tumor suppressor in classical Hodgkin lymphoma cells
Hiromichi Yuki et al.
BLOOD (2013)
Transcriptional Regulation of Germinal Center B and Plasma Cell Fates by Dynamical Control of IRF4
Kyoko Ochiai et al.
IMMUNITY (2013)
PU.1 Level-Directed Chromatin Structure Remodeling at the Irf8 Gene Drives Dendritic Cell Commitment
Joerg Schoenheit et al.
CELL REPORTS (2013)
Proteasome inhibitors in multiple myeloma: 10 years later
Philippe Moreau et al.
BLOOD (2012)
Exploiting Synthetic Lethality for the Therapy of ABC Diffuse Large B Cell Lymphoma
Yibin Yang et al.
CANCER CELL (2012)
The genetic architecture of multiple myeloma
Gareth J. Morgan et al.
NATURE REVIEWS CANCER (2012)
Lenalidomide downregulates the cell survival factor, interferon regulatory factor-4, providing a potential mechanistic link for predicting response
Antonia Lopez-Girona et al.
BRITISH JOURNAL OF HAEMATOLOGY (2011)
C/EBP alpha and PU.1 are involved in distinct differentiation responses of acute promyelocytic leukemia HL-60 and NB4 cells via chromatin remodeling
Jurate Savickiene et al.
DIFFERENTIATION (2011)
Suppression of IRF4 by IRF1, 3, and 7 in Noxa Expression Is a Necessary Event for IFN-γ-Mediated Tumor Elimination
Sujan Piya et al.
MOLECULAR CANCER RESEARCH (2011)
Initial genome sequencing and analysis of multiple myeloma
Michael A. Chapman et al.
NATURE (2011)
MEDICAL PROGRESS Multiple Myeloma
Antonio Palumbo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Vav1 and PU.1 are recruited to the CD11b promoter in APL-derived promyelocytes: Role of Vav1 in modulating PU.1-containing complexes during ATRA-induced differentiation
Federica Brugnoli et al.
EXPERIMENTAL CELL RESEARCH (2010)
Identification of a Primary Target of Thalidomide Teratogenicity
Takumi Ito et al.
SCIENCE (2010)
PU.1 Regulates Positive Regulatory Domain I-Binding Factor 1/Blimp-1 Transcription in Lymphoma Cells
Shruti Desai et al.
JOURNAL OF IMMUNOLOGY (2009)
PU.1 induces apoptosis in myeloma cells through direct transactivation of TRAIL
S. Ueno et al.
ONCOGENE (2009)
Thalidomide for treatment of multiple myeloma: 10 years later
Antonio Palumbo et al.
BLOOD (2008)
Interferon regulatory factor family of transcription factors and regulation of oncogenesis
Akinori Takaoka et al.
CANCER SCIENCE (2008)
New drugs in multiple myeloma: mechanisms of action and phase I/II clinical findings
Enrique M. Ocio et al.
LANCET ONCOLOGY (2008)
IRF4 addiction in multiple myeloma
Arthur L. Shaffer et al.
NATURE (2008)
The interferon regulatory factor family in host defense: Mechanism of action
Keiko Ozato et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
Down-regulation of PU.1 by methylation of distal regulatory elements and the promoter is required for myeloma cell growth
Hiro Tatetsu et al.
CANCER RESEARCH (2007)
A two-step, PU.1-dependent mechanism for developmentally regulated chromatin remodeling and transcription of the c-fms gene
Hanna Krysinska et al.
MOLECULAR AND CELLULAR BIOLOGY (2007)
Lymphoid cell growth and transformation are suppressed by a key regulatory element of the gene encoding PU.1
F Rosenbauer et al.
NATURE GENETICS (2006)
Differential expression of IFN regulatory factor 4 gene in human monocyte-derived dendritic cells and macrophages
A Lehtonen et al.
JOURNAL OF IMMUNOLOGY (2005)
IRF-7 is the master regulator of type-I interferon-dependent immune responses
K Honda et al.
NATURE (2005)
Potential autoregulation of transcription factor PU.1 by an upstream reaulatory element
Y Okuno et al.
MOLECULAR AND CELLULAR BIOLOGY (2005)
Acute myeloid leukemia induced by graded reduction of a lineage-specific transcription factor, PU.1
F Rosenbauer et al.
NATURE GENETICS (2004)
The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma
E Tian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Distal elements are critical for human CD34 expression in vivo
Y Okuno et al.
BLOOD (2002)
Differential regulation of the human and murine CD34 genes in hematopoietic stem cells
Y Okuno et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
Apo2L/TRAIL and Bcl-2-related proteins regulate type I interferon-induced in multiple myeloma
Q Chen et al.
BLOOD (2001)
Share Paper
